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Background: To evaluate and compare dosimetric parameters of volumetric modulated arctherapy (VMAT) and
helical tomotherapy (HT) for non-anaplastic thyroid cancer adjuvant radiotherapy.
Methods: Twelve patients with non-anaplastic thyroid cancer at high risk of local relapse received adjuvant external
beam radiotherapy with curative intent in our institution, using a two-dose level prescription with a simultaneous
integrated boost approach. Each patient was re-planned by the same physicist twice using both VMAT and HT. Several
dosimetric quality indexes were used: target coverage index (proportion of the target volume covered by the reference
isodose), healthy tissue conformity index (proportion of the reference isodose volume including the target volume),
conformation number (combining both previous indexes), Dice Similarity Coefficient (DSC), and homogeneity index
((D2%-D98%)/prescribed dose). Dose-volume histogram statistics were also compared.
Results: HT provided statistically better target coverage index and homogeneity index for low risk PTV in comparison
with VMAT (respectively 0.99 vs. 0.97 (p = 0.008) and 0.22 vs. 0.25 (p = 0.016)). However, HT provided poorer results for
healthy tissue conformity index, conformation number and DSC with low risk and high risk PTV. As regards organs at
risk sparing, by comparison with VMAT, HT statistically decreased the D2% to medullary canal (25.3 Gy vs. 32.6 Gy
(p = 0.003)). Besides, HT allowed a slight sparing dose for the controlateral parotid (Dmean: 4.3 Gy vs. 6.6 Gy (p = 0.032))
and for the controlateral sub-maxillary gland (Dmean: 29.1 Gy vs. 33.1 Gy (p = 0.041)).
Conclusions: Both VMAT and HT techniques for adjuvant treatment of non-anaplastic thyroid cancer provide globally
attractive treatment plans with slight dosimetric differences. However, helical tomotherapy clearly provides a benefit in
term of medullary canal sparing.
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Thyroid cancer is the 18th most common cancer in Europe,
with around 53000 new cases diagnosed in 2012 (2% of the
total) and with reported increases in incidence between
1973 and 2002 from 5.3% (Switzerland) to 155.6% (among
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unless otherwise stated.Differentiated thyroid cancers (DTC) comprise the vast
majority of all thyroid cancers (90%, including 80% of pap-
illary and 10% of follicular thyroid cancers), followed by
medullary thyroid cancers (MTC) (4%), poorly differenti-
ated thyroid cancers (PDTC) (4%), and anaplastic thyroid
cancers (ATC) (1-2%) [2,3].
Tumor histology is a critical determinant of patient
outcomes: DTC is associated with the best survival rates
(10-year relative survival: 93% for papillary carcinoma
and 85% for follicular carcinoma), and ATC with theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and MTC have intermediate prognosis [4]. Besides, sev-
eral histological subtypes of papillary carcinoma have
been described with poorer outcomes compared to clas-
sical papillary carcinoma (diffuse sclerosing and tall cell
variants) [5]. Lymph node metastases represent another
strong prognosis factor of recurrence and reduced sur-
vival especially in patients aged >45 years [6-9]. Contrary
to follicular carcinoma, lymph nodes involvement is
commonly described in classic papillary carcinomas (56%)
and more frequently in aggressive variants (respectively
72% and 67% with diffuse sclerosing and tall cell variants)
and in MTC (55-75%) [5,10,11]. Several other poor prog-
nosis factors have been established with DTC including
age >40-60 years, presence and extent of extrathyroidal
extension (T3, T4), tumor size >1 cm, extent of post-
surgical residual disease, or absence of radioactive iodine
uptake [6,12-14].
In non metastatic stages, the main and first step of
treatment consists of surgery. In case of DTC >1 cm
and/or presence of one of the previous high risk fea-
tures, surgery is followed by radioactive iodine (RAI)
therapy [15].
The role of external beam radiotherapy (EBRT) in thy-
roid cancer has been studied in many retrospective stud-
ies, and only a subset of patients at high risk of local
recurrence may benefit from adjuvant EBRT [15-18].
Due to cervico-mediastinal localization of these cancers,
with several complicated-shape organs at risk around the
thyroid, EBRT can be difficult to plan. Major improve-
ments in radiation therapy in the last decade have first led
to fixed-field intensity-modulated radiotherapy (IMRT),
allowing dose escalation on the target volume as well as
protection of organs at risk (OAR). In the field of thyroid
cancer, only few clinical or dosimetric data exist about
IMRT [19-22]. These data suggest that compared to 3D
conformational radiotherapy, IMRT improves PTV cover-
age and spinal cord sparing, and is associated with less
frequent late morbidity but with no impact on survival
outcomes. Further improvements in treatment optimization
and planning treatment led to better dosimetric perform-
ance with Volumetric Modulated Arctherapy [23] (RapidArc
for Varian Medical System® and VMAT for Elekta®), or
Helical Tomotherapy [24] (Accuray®).
The prolonged survivals obtained for locally advanced
thyroid cancer after adjuvant EBRT [13,16,20,25,26] should
lead us to choose the technique allowing the best OAR
sparing to avoid late toxicities, with optimal planning target
volume coverage. Nevertheless, no comparison between
these two last techniques exists in this way in the field of
thyroid cancer adjuvant radiotherapy.
Therefore, the aim of this retrospective study was thus
to compare volumetric modulated arc-therapy (VMAT
RapidArc from Varian Medical System®) and HelicalTomotherapy (HT) for adjuvant treatment of non-anaplastic
thyroid cancer, in terms of dose distribution to the Planning
Target Volume and OAR protection.Methods
Population
From March 2011 to December 2013, 12 patients with
histologically proven non-anaplastic thyroid cancer were
consecutively irradiated by VMAT or HT at our institu-
tion in a curative intent.
Patient’s characteristics are summarized in Table 1.Therapeutic sequence and indications of EBRT
All the patients underwent external beam radiotherapy
(EBRT) in first-line treatment after initial surgery and
radioactive iodine therapy for all non medullary carcin-
omas (100 mCi). The initial surgery consisted of total thy-
roidectomy with lymph node dissection for all 12 patients
(central compartment neck dissection for all patients and
lateral neck dissection for ten patients).
No patient received chemotherapy.
Indication of EBRT was as follows: node extracapsular
spread and/or microscopic or macroscopic residual dis-
ease following surgery.Planning target volumes, organs at risk delineation and
dose prescription
High risk of recurrence clinical target volume (CTV)
included primary tumor bed with microscopic positive
margins, residual gross tumor at first post-surgical assess-
ment, or areas of nodal extra-capsular spread, and was
treated with high dose EBRT. Low risk CTV included
primary and nodal micro-metastatic disease (including
level VII nodes, according to the classical patterns of
relapse after radiotherapy [25]), and was treated with
low dose EBRT.
Level II nodes were included in low risk CTV in nine
patients and in high risk CTV in two patients. Levels
III-IV-VI nodes were included in high risk CTV in seven
patients.
PTV was built by 3D-automatic expansion of CTV
with a 3 millimeters margin.
Among the twelve patients considered: ten patients
received a high dose/low dose prescription, one patient
received only a high dose prescription and one patient
received only a low dose prescription. High risk PTV
was treated according to simultaneous integrated boost
technique to deliver 63 Gy by 30 fractions of 2.1 Gy,
whereas low risk PTV was treated with 54 Gy by 30
fractions of 1.8 Gy.
According to ICRU 83 report, the dose prescription
referred to the median dose (D50%).
Table 1 Patient and tumor characteristics
Patient Pathological
subtypes






PTV 63 PTV 54
Volume (cm3)/ Volume (cm3)/
Height (cm) Height (cm)
1 Medullary Right lobe T3N1a R: VI Y R1 298.55/13.26 534.84/18.42
2 Medullary Left lobe T4aN1b R: VI Y R1 490.76/14.54 954.89/20.62
L: II, III, V, VI
3 Vesicular Bilateral T4aN0 - - R2 254.54/11.36 500.39/13.36
4 Medullary Right lobe T2N1b R: IIA, III, IV, V, VI Y R0 - 641.07/20.78
L: VI
5 Medullary Bilateral T3N1b L: IIA, VI Y R1 93.3/10.62 262.36/18.33
R: VI
6 Medullary Right lobe T2N1b R: III, IV, VI Y R0 206.97/13.37 545.01/18.66
7 Papillary Bilateral T4aN1a R: VI Y R1 124.11/5.9 -
8 Papillary Left lobe T4aN1b L: III, IV, VI Y R1 39.39/4.24 247.87/14.92
9 Medullary Right lobe T3N1b R: III, VI Y R1 83.52/8.59 300.35/16.07
10 Medullary Left lobe T3N1b L: IV, VI Y R1 405.82/22.43 596.87/22.43
R: VI, VII
11 Papillary Bilateral T3N1b R: IV, VI Y R0 51.36/6.02 361.89/17.35
12 Papillary Left lobe T4aN1a L: VI N R1 95.08/8.44 201.39/13.12
Average 194.85/10.8 467.91/17.64
R = right; L = left; R0 = no residual tumor; R1 =microscopic residual tumor; R2 =macroscopic residual tumor; Y = yes; N = No.
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glands, sub-maxillary glands, larynx, oral cavity, esopha-
gus and brachial plexus.
Finally, healthy tissue (non-tumor tissue volume) was
defined as:
Volume between the vertex and the apex of xyphoïd
process – (PTV63 U PTV54)
All contours were approved by a single physician
widely experimented in head and neck cancers radi-
ation oncology.
Dose volume constraints and inverse treatment
planning
Treatment planning was recalculated for each patient
with both VMAT and HT by the same physicist (experi-
enced in both techniques).
All the VMAT treatment plans were computed
using the Eclipse TPS v8.9 (Varian Medical Systems,
Inc., Palo Alto, CA). Dose calculation was performed
using the Anisotropic Analytical Algorithm (AAA)
with a calculation grid resolution of 2.5 mm. Treat-
ment plans were optimized for a Varian 2100 iX clinac
equipped with a Millenium 120 MLC. Each VMAT
plan was designed using two 6 MV photon coplanararcs of 360°: clockwise (CW) and counterclockwise
(CCW) divided in 177 control points. The collimator
angle was equal to 15° and 345° for the CW and the
CCW arcs respectively. The optimization was based
on the PRO II algorithm. Normal Tissue Objective
(NTO) algorithm was used in the VMAT planning in
order to minimize the dose deposited outside of the
PTV. The NTO was used with a distance from the
target of 3 mm, a start dose of 100%, an end dose of
30% and a fall off of 0.1. The maximal dose rate was
set to 600 MU/min.
HT used a helical slice 6 MV photon beam, modu-
lated in intensity using binary MLCs. For all plans,
we used a field width of 2.5 cm with a pitch value of
0.287 and a nominal modulation factor of 2.5. Plans
were optimized using the Tomotherapy Hi-Art TPS,
version 4.2.1 (Tomotherapy Inc. Madison, WI). The
dose distribution for each beamlet was calculated using a
convolution/superposition algorithm. The optimization
process used the least mean squares method to minimize
the objective function.
During planning, the first objective was to ensure PTV
coverage. The criteria for plan validation were: more
than 95% of the prescribed dose to more than 95% of
the PTV, more than 90% of the prescribed dose to more
than 98% of the PTV, and less than 107% of the prescribed
Khalifa et al. Radiation Oncology 2014, 9:247 Page 4 of 11
http://www.ro-journal.com/content/9/1/247dose to less than 2% of the PTV. The D50% had to be as
close as possible to 54Gy and 63Gy for PTV54 Gy and
PTV63 Gy respectively.
The secondary objective was to minimize OAR doses
as much as possible. For esophagus and brachial
plexus, no optimization criteria were defined, but
sparing was allowed by the NTO algorithm in VMATTable 2 Dose-volume constraints for PTVs and OARs used for
VMAT
Structures Optimization objectives Optim
PTV 63 Gy D50% = 63 Gy Very H
Dmin > 100% Dpresc HR Very H
Dmax < 102% Dpresc HR Very H
PTV 54 Gy - -
PTV 54 Gy – PTV 63 Gy Dmin > 100%Dpresc LR Very H
Dmax < 95% Dpresc HR High
D5% < 105%Dpresc LR High
PTV 54 Gy –(PTV 63 Gy +1 cm) Dmax < 95%Dpresc LR High
PRV medullary canal Dmax < 35Gy High
D2% < 33 Gy
Ipsilateral parotid gland - PTVs V10Gy < 45% Mediu
V25Gy < 30%
V40Gy < 15%
Controlateral parotid gland - PTVs V10Gy < 45% High
V25Gy < 30%
V40Gy < 15%
Mandible - PTVs D5% < 55Gy Mediu
D50% < 30Gy
Larynx - PTVs Dmax < 55Gy Mediu
D50% < 30Gy
D95% < 15Gy
Oral cavity - PTVs Dmax < 55Gy Mediu
D50% < 30Gy
D95% < 15Gy
Ipsilateral sub-maxillary gland - PTVs D30% < 50Gy Mediu
D50% < 30Gy
Controlateral sub-maxillary gland - PTVs D30% < 50Gy High
D50% < 30Gy
Dx% = dose received by x% of structure volume; VxGy = percent structure volume of
Dpresc HR = prescribed dose on high risk PTV = 63 Gy; Dpresc LR = prescribed dose onand by non-anatomical optimization “dummy volumes”
in HT.
After each planning, we made sure that it was reason-
ably deliverable.
The optimization objectives for PTV and OAR with
respective priorities and the criteria for plan validation
are summarized in Tables 2 and 3.optimization
Helical tomotherapy
ization priorities Optimization objectives Optimization priorities
igh Dmin = 63 Gy Very high
igh D50% = 63 Gy Very high
igh Dmax = 63 Gy Very high
Dmin = 54 Gy High
D50% = 54 Gy High
Dmax = 54 Gy High
igh - -
- -
Dmax < 30 Gy High
D2% < 28Gy








m Dmax < 65Gy Medium
D5% < 55Gy
D50% < 30Gy
m Dmax < 55Gy Medium
D50% < 30Gy
D95% < 15Gy
m Dmax < 55Gy Medium
D50% < 30Gy
D95% < 15Gy
m Dmax < 55Gy Medium
D30% < 50Gy
D50% < 30Gy




low risk PTV =54 Gy.
Table 3 Criteria for plan validation
Structures Dose-constraint
PTV 63 Gy D50% = 63 Gy
D95% > 95%Dpresc HR
D98% > 90%Dpresc HR
D2% < 107%Dpresc HR
PTV 54 Gy D95% > 95%Dpresc LR
D98% > 90%Dpresc LR
PRV medullary canal Dmax < 45Gy




Mandible Dmean < 30Gy
Dmax < 70Gy
Larynx Dmean < 30Gy
Dmax < 55Gy
Oral cavity Dmean < 30Gy
Dmax < 55Gy
Sub-maxillary glands* Dmean < 40Gy
*At least one.
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Plans quality was first assessed according to simple cri-
teria from ICRU 83: near-minimal dose (D98%), near-
maximal dose (D2%) and median dose (D50%).
Other indexes were used to compare both treatment
techniques:
1. Dose conformity [27]:
– Target coverage index (TCov-I) corresponds
to the proportion of target volume covered
by the reference isodose (95% of the prescribed
dose), regardless of healthy tissue [28]:
TCov ‐ I = VTIR/VT
with VT: target volume (ie PTV),
and VTIR: target volume covered by the
reference isodose volume (95% of the
prescribed dose).
– Healthy tissue conformity index (HTConf-I)
corresponds to the proportion of the reference
isodose volume including the target volume.
Indirectly, it refers to the volume of healthy
tissue included in the reference isodose [28]:HTConf‐I ¼ VTIR=VIR
with VIR: reference isodose volume (95% of
prescribed dose)– Conformation number (CN) is a global index
which provides information as well on tumor
coverage as on protection of healthy tissue [29]:CN ¼ VTIR=VTð Þ x VTIR=VIRð Þ
– Dice Similarity Coefficient (DSC) is defined inICRU 83 report as the ratio between twice the
tumor volume covered by the reference isodose
and the sum of tumor volume and reference
isodose volume:DSC ¼ 2xVTIR= VT þ VIRð Þ
– The ideal value of these four indexes is 1.2. Dose homogeneity:
Homogeneity index HIð ÞICRU ¼ D2%−D98%ð Þ=D50%
The ideal value of HI is 0.
3. For healthy tissue, we defined integral dose (ID) to the
non tumor-tissue volume (NTID) as follows [30,31]:
NTID ¼ ID body between the vertex and the apex of xyphoid processð Þ
– ID PTVs PTV54 U PTV63ð Þ
where:ID structureS Joulesð Þ ¼ DmeanS Gyð Þ x VolumeS cm3ð Þ x
densityS kg:cm
‐3ð Þ;
¼ DmeanS Gyð Þ x
VolumeS cm3ð Þwith density ≈ 1;
Statistical analysis
Patients’ characteristics were described using median
and range for quantitative data, and frequency and per-
cent for qualitative data.
The comparison between the two techniques in the
paired population was made using the Wilcoxon signrank
test. All tests were two-tailed and p < 0.05 was considered
to indicate statistical significance. All statistical analyses
were done with STATA 12.0 software (StataCorp. 2011.
Stata Statistical Software: Release 12. College Station,
TX: StataCorp LP).
This study was approved by the scientific board of the
multidisciplinary head-and-neck tumor institutional group.
Results
The results are summarized in Tables 4 and 5.
High risk PTV
In comparison with VMAT, HT provided poorer results
for HTConf-I (0.77 vs. 0.85 (p = 0.016)), CN (0.74 vs.
0.78 (p = 0.033)) and DSC (0.85 vs. 0.88 (p = 0.033)).




VMAT Helical Tomotherapy P
PTV 63 D2% (Gy) 65.4 (64.2-67.0) 64.9 (64.1-66.0) 0.131
D50% (Gy) 63 (63.0-63.9) 62.9 (62.8-63.1) 0.062
D98% (Gy) 58.4 (57.4-60.7) 59.3 (57.0-60.7) 0.248
TCov-I 0.94 (0.90-0.99) 0.96 (0.91-0.99) 0.091
HTConf-I 0.85 (0.77-0.92) 0.77 (0.66-0.94) 0.016*
CN 0.78 (0.76-0.87) 0.74 (0.62-0.85) 0.033*
DSC 0.88 (0.87-0.93) 0.85 (0.77-0.92) 0.033*
HI 0.11 (0.06-0.15) 0.09 (0.05-0.13) 0.109
PTV 54 D2% (Gy) 64.9 (56.3-66.4) 64.3 (55.0-65.7) 0.109
D50% (Gy) 57.5 (54.0-62.3) 57.1 (54.0-61.9) 0.168
D98% (Gy) 51.0 (48.6-52.0) 51.8 (50.5-53.6) 0.016*
TCov-I 0.97 (0.90-0.99) 0.99 (0.97-1.00) 0.008*
HTConf-I 0.84 (0.71-0.89) 0.63 (0.51-0.69) 0.003*
CN 0.76 (0.69-0.82) 0.62 (0.50-0.67) 0.003*
DSC 0.86 (0.78-0.90) 0.77 (0.67-0.81) 0.003*
HI 0.25 (0.12-0.29) 0.22 (0.06-0.26) 0.016*
TCov-I = Target Coverage Index; HTConf-I = Healthy Tissue Conformity Index;
CN = Conformation Number; DSC = Dice Similarity Coefficient; HI = Homogeneity
Index; * = p < 0.05.
Table 5 Median (range) dosimetric results for organs at risk a
Organ Dose-volume index VM
Medullar canal D2% (Gy) 32.6
PRV medullar canal D2% (Gy) 34.3
I parotid gland V26Gy (%) 31.1
Dmean (Gy) 19.9
C parotid gland V26Gy (%) 0 (0
Dmean (Gy) 6.6
I submaxillary gland Dmean (Gy) 36.1
C submaxillary gland Dmean (Gy) 33.1
Mandible D2% (Gy) 35.6
Oral cavity Dmean (Gy) 17.2
Larynx D2% (Gy) 60.8
Dmean (Gy) 45.9
Esophagus D2% (Gy) 60.9
I brachial plexus D2% (Gy) 62.7
C brachial plexus D2% (Gy) 54.4
ID body (Joules) 138
NTID (Joules) 117
Dx% = dose received by x% of structure volume; VxGy = percent structure volume of
ID = Integral Dose; NTID = Normal Tissue Integral Dose; * = p < 0.05.
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however it was not statistically significant (respectively:
0.96 vs. 0.94 (p = 0.091) and 0.09 vs. 0.11 (p = 0.109)).Low risk PTV
In comparison with VMAT, HT allowed an improvement
in TCov-I and HI: respectively 0.99 vs. 0.97 (p = 0.008)
and 0.22 vs. 0.25 (p = 0.016).
On the other hand, we found poorer results with HT
for HTConf-I, CN and DSC: respectively 0.63 vs. 0.84
(p = 0.003), 0.62 vs. 0.76 (p = 0.003) and 0.77 vs. 0.86
(p = 0.003).Organs at risk and healthy tissue
By comparison with VMAT, HT significantly improved
the D2% to medullary canal and to PRV (planning organ
at risk volume) medullary canal: respectively 25.3 Gy vs.
32.6 Gy (p = 0.003) and 27.2 Gy vs. 34.3 Gy (p = 0.003).
As for parotid sparing, we failed to find a strong dosi-
metric benefit with HT compared to VMAT (except a
decrease in Dmean to the controlateral parotid with HT:
4.3Gy vs. 6.6Gy (p = 0.032)).
Besides, Dmean to the controlateral submaxillary gland
was also decreased with HT (29.1 Gy vs. 33.1 Gy (p = 0.041)).
On the other hand, HT provided a higher D2% to
mandible (42.6 Gy vs. 35.6 Gy (p = 0.01)).
Finally, there was higher NTID with HT compared to
VMAT (124.6 Joules vs. 117.0 Joules (p = 0.008)).
These results are illustrated in Figures 1 and 2.nd healthy tissue
AT Helical tomotherapy P
(30.1-39.0) 25.3 (23.0-34.6) 0.003*
(31.6-40.4) 27.2 (24.1-35.1) 0.003*
(0–42.6) 33.8 (0–45.9) 0.812
(0–24.4) 19.5 (0–25.8) 0.812
–49.3) 0 (0–47.3) 0.85
(0–28.1) 4.3 (0–27.2) 0.032*
(15.4-44.6) 34.5 (24.7-44.6) 0.623
(3.4-41.9) 29.1 (1.5-39.6) 0.041*
(1.4-52.2) 42.6 (0.9-58.0) 0.01*
(0.5-27.4) 17.8 (0.5-32.2) 0.075
(49.2-64.9) 60.7 (43.6-65.0) 0.209
(10.8-62.5) 39.2 (25.0-62.6) 0.638
(47.7-63.7) 57.5 (41.6-64.7) 0.049*
(44.1-67.4) 62.5 (46.4-64.6) 0.209
(29.7-58.5) 54.2 (26.8-55.1) 0.308
.5 (54.9-242.3) 149.5 (72.5-271.0) 0.008*
.0 (47.0-201.6) 124.6 (64.7-226.3) 0.008*
xGy; I = ipsilateral; C = controlateral.
VMAT
HT
Figure 1 Dose distribution in color-wash for one representative patient with VMAT (top) and HT (bottom). Red line: PTV63. This figure
shows a color-wash of the dose distribution from 25Gy to 63Gy in VMAT and HT for one patient: a better medullary canal sparing is obtained with
HT compared to VMAT.
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Figure 2 Dose volume histogram of PTV63 Gy, PTV54 Gy, medullary canal, ipsilateral and controlateral parotid for one representative
patient using VMAT and HT.
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To our knowledge, no previous study compared VMAT
and HT specifically for thyroid cancer treatment.
We found that HT for non anaplastic-thyroid cancer
provided statistically better tumor coverage index and
homogeneity index in comparison with VMAT essen-
tially for low risk PTV. On the other side, we found
poorer results with HT for healthy tissue conformity
index, conformation number and Dice Similarity Coeffi-
cient for low risk and for high risk PTV. Regarding OAR,
by comparison with VMAT, HT mainly statistically
decreased the maximum dose to the medullary canal.
VMAT and HT represent the ultimate evolution of
IMRT since they both allow highly modulated treat-
ments. However, few data are available regarding their
direct comparison in the anatomical sites of thyroid can-
cer irradiation: i.e. median and low cervical regions and
upper mediastinum.
For oropharyngeal cancer, several studies are available
comparing HT and VMAT. Clemente et al. compared in
eight patients also VMAT with both IMRT and HT for a
three-dose-level prescription. The same benefit was found
for HT compared to VMAT in target coverage and dose
homogeneity, but also in conformity [32]. However, the
authors did not use the same indexes. Indeed, the con-
formity index referred to the ratio between the volume of
the reference isodose of the low risk PTV and the volume
of all PTV (RTOG conformity index). This last index pre-
sents a major drawback: it does not take into account the
degree of spatial intersection of the two volumes, and is
rather adapted to stereotactic radiosurgery. For this rea-
son, we decided not to use this index. Van gestel et al.
found that compared to VMAT RapidArc®, HT provided
better homogeneity index for high risk PTV but poorer
homogeneity index for low risk PTV. They also found
that for high risk PTV (but not for low risk PTV), HTprovided poorer conformity index than VMAT RapidArc®
(defined as our healthy tissue conformity index), that quite
agrees with our results [33]. In another study, VMAT
RapidArc® was surprisingly globally better in terms of
homogeneity index for low risk and intermediate risk
PTV and DSC for intermediate and high risk PTV [31].
No study compared VMAT and HT for hypopharyn-
geal/laryngeal cancers.
Finally, only one study compared VMAT and HT among
patients with superior mediastinal tumors (early stage
mediastinal Hodgkin’s Lymphoma treated with 30 Gy
Involved Nodes Radiation Therapy). The authors found a
better homogeneity index for HT and similar results for
Conformation Number and for OAR sparing (breast, lung,
heart, thyroid gland) in terms of both Dmean and volumes
receiving low doses to high doses. (Only a decrease in
lungs V10Gy and V15Gy was shown in HT). [34]
As no study compared precisely these techniques for
thyroid cancers, this prompted us to perform this dosi-
metric comparison. We took a particular attention to
perform the most credible comparison: all contours were
approved by a single physician and all plans were gener-
ated by a single physicist, both strongly experimented in
both VMAT and HT.
Our results compared to VMAT seem to be coherent
with physical characteristics of helical tomotherapy dose
distribution. First, opposed to IMRT step-and-shoot char-
acterized by multi-angular beams, HT and VMAT can
adopt 360° rotation, which allows delivering a more homo-
geneous dose in the target area. Nevertheless, in order to
improve dose sparing to an OAR or an area, it should be
noted that VMAT can use partial gantry rotation with
avoidance sectors. In the same way, to achieve this dose
sparing goal, HT cannot use partial arcs but it can use the
directional block technique, where the beams are forbidden
from entering through the defined area but can exit
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tional block) are rather adapted to lateral target volumes,
and therefore have not been used in this study of thyroid
cancers (with concave median target volumes). Besides,
HT is equipped with a binary MLC with very fast leaf tran-
sition times achieved by using a compressed air system.
This combined with the helical fashion in which HT de-
livers radiation allows a greater degree of intensity modula-
tion compared with VMAT: it could thus explain a more
homogeneous dose in the target area and a better coverage
of the target as we showed. The HTConf-I refers to the ex-
tent to which the reference isodose diverges from the tar-
get volume. As far the poorer results for HTConf-I in
high risk PTV, this could be explained by differences
in optimization techniques: contrary to HT, we defined
for VMAT several optimization sub-volumes (“PTV54 –
PTV 63” and “PTV54 – (PTV63 + 1 cm)”) to control the
dose gradient between high dose and low dose PTV. A
way to improve this index in HT could be the creation
of a “ring” around the high dose PTV with specific
optimization criteria. The poorer results for HTConf-I
in low risk PTV could be explained by the process of HT
dose delivery. Indeed, the fixed filed size and the lack of
dynamic jaws in most helical tomotherapies (unlike new
generation of tomotherapy) lead HT to deliver a relatively
larger “dose spread” in the superior–inferior direction.
In this respect, normal-tissue integral dose is a burn-
ing issue with HT and represents a classical disadvantage
of this technique. Indeed, as we reported here, several
data suggest that HT increases NTID and healthy tissue
volumes irradiated with low dose radiation compared to
VMAT [31,35], with an undetermined risk of second
cancer. Nevertheless, a few data suggest that new dy-
namic jaws HTs could now decrease the integral dose
compared to regular HTs [36]. Furthermore, even with
non-dynamic jaws HTs, it should be noted that a smaller
field width (1 cm instead of 2.5 cm as used in our study)
could also reduce the normal tissue dose spread, but at
the cost of an increased treatment time. (However, due
to the relatively small volumes of PTV in thyroid cancer
radiotherapy, the treatment time might not be dramatic-
ally increased).
Finally, all these data taken together can be confusing
to choose between VMAT and HT for thyroid cancer
treatment.
Indeed, in all the previous dosimetric studies men-
tioned, as in ours, the dosimetric differences linked to
dose distribution within or just around the PTV are
slight, and are probably likely to have no clinical effect
in term of local control.
However, the main result of our study is represented
by a statistically significant strong decrease in the D2%
to medullary canal and its PRV. And this data can be of
the utmost importance for several reasons.Firstly, compared to locally advanced HNSCC patients,
patients with advanced thyroid cancers and adjuvant
EBRT present prolonged survival regardless of the tech-
nique (3D vs. IMRT) [13,16,20,25,26]; therefore, late
toxicities have to be considered to choose the best
technique, and HT could be interesting in this way.
Secondly, patients with non-anaplastic thyroid cancers
with indication of EBRT always present aggressive dis-
ease with high risk of loco-regional relapse and even of
distant relapse (like vertebral metastatic relapse). These
patients can thus draw benefits from another irradiation
which can be problematic in term of previous dose to
OAR, and precisely spinal cord. Finally, among Hodgkin
Lymphoma survivors, an estimated 5- to 15-fold increased
risk of radio-induced thyroid cancer compared with the
normal population has been reported, especially among
female treated at a young age [37-41]. These patients may
also dramatically beneficiate from a decreased D2% to the
spinal cord with HT.
Concerning parotid and sub-maxillary gland sparing,
we found a slight decrease in Dmean to the controlateral
glands in HT. However, this benefit is difficult to appre-
ciate since salivary glands are not crucial OAR in thyroid
cancer irradiation, except when level II has to be treated
in the high dose PTV. Besides, we could note that our
good results in parotid sparing (in VMAT or in HT) are
widely explained by the fact that only two patients had
level II nodes in high risk PTV.
We must note however that better OAR sparing with
HT is obtained only for high priority penalty OAR, with
poorer results for mandible which priority penalty is
low, as also reported by Clemente et al. [32].
Last, these results on better high priority OAR sparing
are not in contradiction with the poorer healthy tissue
conformity index in HT. Indeed, the better gradient dose
of HT, the better dose homogeneity and the other char-
acteristics mentioned above lead to strictly respect high
priority objectives but at the cost of a large dose spread,
with thus poorer healthy tissue conformity.
Conclusion
In this study, twelve patients with aggressive non-
anaplastic thyroid cancer were planned with both VMAT
and helical tomotherapy.
Both techniques provided globally attractive treatment
plans although slight differences were found in terms of
homogeneity or target coverage in favor of HT, or in
terms of healthy tissue conformity, conformation num-
ber or DSC in favor of VMAT. These slight differences
have probably no clinical impact on local control.
However, better medullary canal sparing was obtained
with HT, which can be widely interesting in case of re-
irradiation, for patients with aggressive disease with high
risk of loco-regional relapse or among previously irradiated
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possible, HT should be preferred in case of non anaplastic
thyroid cancer radiotherapy.
Annex 1. TNM staging for non-anaplastic thyroid
cancer (7th edition)
T categories:
TX: Primary tumor cannot be assessed.
T0: No evidence of primary tumor.
T1: The tumor is 2 cm across or smaller and has not
grown out of the thyroid.
T1a: The tumor is 1 cm across or smaller and has not
grown outside the thyroid.
T1b: The tumor is larger than 1 cm but not larger
than 2 cm across and has not grown outside of the
thyroid.
T2: The tumor is between 2 cm and 4 cm across and
has not grown out of the thyroid.
T3: The tumor is larger than 4 cm or it has begun to
grow a small amount into nearby tissues outside the
thyroid.
T4a: The tumor is any size and has grown extensively
beyond the thyroid gland into nearby tissues of the neck,
such as the larynx, trachea, esophagus, or the nerve to
the larynx.
T4b: A tumor of any size that has grown either back
toward the spine or into nearby large blood vessels.
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